Rx-360 Receives Mixed Reviews on Plan to Share Drug Industry Audits

The drug industry is expressing some skepticism about relying on an Rx-360 Consortium plan to conduct and share supply-chain audits as the months-old consortium sets up working groups toward that end. “It’s important that industry understand what they’re getting and verify the information,” Steven Niedelman, senior consultant with Crowell & Moring, said at the FDAnews Supplier Quality Management Congress last week. Rx-360, which launched in June, would choose suppliers for audits based on member input, and members can view audit results on a subscription basis.
Drug Industry Daily